-
1
-
-
73349084973
-
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study
-
Heng DY, Xie W, Regan MM, et al: Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study. J Clin Oncol 27:5794-5799, 2009
-
(2009)
J Clin Oncol
, vol.27
, pp. 5794-5799
-
-
Heng, D.Y.1
Xie, W.2
Regan, M.M.3
-
2
-
-
0032772880
-
Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma
-
Motzer RJ, Mazumdar M, Bacik J, et al: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530-2540, 1999
-
(1999)
J Clin Oncol
, vol.17
, pp. 2530-2540
-
-
Motzer, R.J.1
Mazumdar, M.2
Bacik, J.3
-
3
-
-
84923445330
-
Kidney cancer
-
version 3.2015
-
Motzer RJ, Jonasch E, Agarwal N, et al: Kidney cancer, version 3.2015. J Natl Compr Canc Netw 13:151-159, 2015
-
(2015)
J Natl Compr Canc Netw
, vol.13
, pp. 151-159
-
-
Motzer, R.J.1
Jonasch, E.2
Agarwal, N.3
-
4
-
-
84955488717
-
Updated EAU guidelines for clear cell renal cancer patients who fail VEGF targeted therapy
-
Powles T, Staehler M, Ljungberg B, et al: Updated EAU guidelines for clear cell renal cancer patients who fail VEGF targeted therapy. Eur Urol 69:4-6, 2016
-
(2016)
Eur Urol
, vol.69
, pp. 4-6
-
-
Powles, T.1
Staehler, M.2
Ljungberg, B.3
-
5
-
-
84969523091
-
Prescribing preferences in the first-line treatment for patients with metastatic renal cell carcinoma in the United States
-
Hackshaw MD, Holmes M, Lankford M, et al: Prescribing preferences in the first-line treatment for patients with metastatic renal cell carcinoma in the United States. Clin Genitourin Cancer 14:e479-e487, 2016
-
(2016)
Clin Genitourin Cancer
, vol.14
, pp. e479-e487
-
-
Hackshaw, M.D.1
Holmes, M.2
Lankford, M.3
-
6
-
-
84975268061
-
Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma
-
Carlo MI, Voss MH, Motzer RJ: Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma. Nat Rev Urol 13:420-431, 2016
-
(2016)
Nat Rev Urol
, vol.13
, pp. 420-431
-
-
Carlo, M.I.1
Voss, M.H.2
Motzer, R.J.3
-
7
-
-
84882781441
-
Pazopanib versus sunitinib in metastatic renal-cell carcinoma
-
Motzer RJ, Hutson TE, Cella D, et al: Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369:722-731, 2013
-
(2013)
N Engl J Med
, vol.369
, pp. 722-731
-
-
Motzer, R.J.1
Hutson, T.E.2
Cella, D.3
-
8
-
-
33846181370
-
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
-
Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124, 2007
-
(2007)
N Engl J Med
, vol.356
, pp. 115-124
-
-
Motzer, R.J.1
Hutson, T.E.2
Tomczak, P.3
-
9
-
-
77949890945
-
Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial
-
Sternberg CN, Davis ID, Mardiak J, et al: Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 28:1061-1068, 2010
-
(2010)
J Clin Oncol
, vol.28
, pp. 1061-1068
-
-
Sternberg, C.N.1
Davis, I.D.2
Mardiak, J.3
-
10
-
-
84901844215
-
First-, second-, third-line therapy for mRCC: Benchmarks for trial design from the IMDC
-
Ko JJ, Choueiri TK, Rini BI, et al: First-, second-, third-line therapy for mRCC: Benchmarks for trial design from the IMDC. Br J Cancer 110:1917-1922, 2014
-
(2014)
Br J Cancer
, vol.110
, pp. 1917-1922
-
-
Ko, J.J.1
Choueiri, T.K.2
Rini, B.I.3
-
11
-
-
55949101858
-
Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen
-
Bommi-Reddy A, Almeciga I, Sawyer J, et al: Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen. Proc Natl Acad Sci USA 105:16484-16489, 2008
-
(2008)
Proc Natl Acad Sci USA
, vol.105
, pp. 16484-16489
-
-
Bommi-Reddy, A.1
Almeciga, I.2
Sawyer, J.3
-
12
-
-
0037478437
-
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
-
Pennacchietti S, Michieli P, Galluzzo M, et al: Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3: 347-361, 2003
-
(2003)
Cancer Cell
, vol.3
, pp. 347-361
-
-
Pennacchietti, S.1
Michieli, P.2
Galluzzo, M.3
-
13
-
-
84907192193
-
Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET
-
Rankin EB, Fuh KC, Castellini L, et al: Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. Proc Natl Acad Sci USA 111:13373-13378, 2014
-
(2014)
Proc Natl Acad Sci USA
, vol.111
, pp. 13373-13378
-
-
Rankin, E.B.1
Fuh, K.C.2
Castellini, L.3
-
14
-
-
84939262957
-
Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma
-
Yu H, Liu R, Ma B, et al: Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma. Br J Cancer 113:616-625, 2015
-
(2015)
Br J Cancer
, vol.113
, pp. 616-625
-
-
Yu, H.1
Liu, R.2
Ma, B.3
-
15
-
-
84873832718
-
c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma
-
Gibney GT, Aziz SA, Camp RL, et al: c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol 24: 343-349, 2013
-
(2013)
Ann Oncol
, vol.24
, pp. 343-349
-
-
Gibney, G.T.1
Aziz, S.A.2
Camp, R.L.3
-
16
-
-
68049096311
-
Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival
-
Gustafsson A, Martuszewska D, Johansson M, et al: Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival. Clin Cancer Res 15:4742-4749, 2009
-
(2009)
Clin Cancer Res
, vol.15
, pp. 4742-4749
-
-
Gustafsson, A.1
Martuszewska, D.2
Johansson, M.3
-
17
-
-
84961287855
-
Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models
-
Ciamporcero E, Miles KM, Adelaiye R, et al: Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models. Mol Cancer Ther 14:101-110, 2015
-
(2015)
Mol Cancer Ther
, vol.14
, pp. 101-110
-
-
Ciamporcero, E.1
Miles, K.M.2
Adelaiye, R.3
-
18
-
-
84941670032
-
Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
-
Zhou L, Liu XD, Sun M, et al: Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene 35:2687-2697, 2016
-
(2016)
Oncogene
, vol.35
, pp. 2687-2697
-
-
Zhou, L.1
Liu, X.D.2
Sun, M.3
-
19
-
-
83355166909
-
Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth
-
Yakes FM, Chen J, Tan J, et al: Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 10:2298-2308, 2011
-
(2011)
Mol Cancer Ther
, vol.10
, pp. 2298-2308
-
-
Yakes, F.M.1
Chen, J.2
Tan, J.3
-
20
-
-
84946552683
-
Cabozantinib versus everolimus in advanced renal-cell carcinoma
-
Choueiri TK, Escudier B, Powles T, et al: Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1814-1823, 2015
-
(2015)
N Engl J Med
, vol.373
, pp. 1814-1823
-
-
Choueiri, T.K.1
Escudier, B.2
Powles, T.3
-
21
-
-
84991063392
-
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): Final results from a randomised, open-label, phase 3 trial
-
Choueiri TK, Escudier B, Powles T, et al: Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): Final results from a randomised, open-label, phase 3 trial. Lancet Oncol 17:917-927, 2016
-
(2016)
Lancet Oncol
, vol.17
, pp. 917-927
-
-
Choueiri, T.K.1
Escudier, B.2
Powles, T.3
-
22
-
-
57849117384
-
New response evaluation criteria in solid tumours: Revised RECIST guideline
-
version 1.1
-
Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
-
(2009)
Eur J Cancer
, vol.45
, pp. 228-247
-
-
Eisenhauer, E.A.1
Therasse, P.2
Bogaerts, J.3
-
24
-
-
84856159566
-
Targeted therapies for renal cell carcinoma: Review of adverse event management strategies
-
Eisen T, Sternberg CN, Robert C, et al: Targeted therapies for renal cell carcinoma: Review of adverse event management strategies. J Natl Cancer Inst 104:93-113, 2012
-
(2012)
J Natl Cancer Inst
, vol.104
, pp. 93-113
-
-
Eisen, T.1
Sternberg, C.N.2
Robert, C.3
-
25
-
-
85007476856
-
Contemporary treatment of metastatic renal cell carcinoma
-
Stukalin I, Alimohamed N, Heng DY: Contemporary treatment of metastatic renal cell carcinoma. Oncol Rev 10:295, 2016
-
(2016)
Oncol Rev
, vol.10
, pp. 295
-
-
Stukalin, I.1
Alimohamed, N.2
Heng, D.Y.3
-
26
-
-
79953307244
-
Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib
-
Beuselinck B, Oudard S, Rixe O, et al: Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol 22:794-800, 2011
-
(2011)
Ann Oncol
, vol.22
, pp. 794-800
-
-
Beuselinck, B.1
Oudard, S.2
Rixe, O.3
-
27
-
-
84879689379
-
Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma
-
Motzer RJ, Escudier B, Bukowski R, et al: Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. Br J Cancer 108:2470-2477, 2013
-
(2013)
Br J Cancer
, vol.108
, pp. 2470-2477
-
-
Motzer, R.J.1
Escudier, B.2
Bukowski, R.3
-
28
-
-
84895059211
-
Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy
-
McKay RR, Kroeger N, Xie W, et al: Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol 65:577-584, 2014
-
(2014)
Eur Urol
, vol.65
, pp. 577-584
-
-
McKay, R.R.1
Kroeger, N.2
Xie, W.3
-
29
-
-
84946607195
-
Nivolumab versus everolimus in advanced renal-cell carcinoma
-
Motzer RJ, Escudier B, McDermott DF, et al: Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803-1813, 2015
-
(2015)
N Engl J Med
, vol.373
, pp. 1803-1813
-
-
Motzer, R.J.1
Escudier, B.2
McDermott, D.F.3
-
30
-
-
84920828671
-
Dual effectsof atargeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine
-
Kwilas AR, Ardiani A, Donahue RN, et al: Dual effectsof atargeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine. J Transl Med 12:294, 2014
-
(2014)
J Transl Med
, vol.12
, pp. 294
-
-
Kwilas, A.R.1
Ardiani, A.2
Donahue, R.N.3
|